TYK2, a Janus kinase family member, mediates signaling from pro-inflammatory cytokines such as type I interferons, IL-12 and IL-23. In multiple sclerosis (MS), chronic CNS inflammation involves glial activation and immune cell infiltration, making TYK2 inhibition a potential strategy to reduce neuroinflammation.
Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024.
